[New therapeutic approach to pancreatic cancer by monoclonal antibodies].
作者:
Sawada(T),Chung(Y S),Sowa(M)
状态:
发布时间1996-11-21
, 更新时间 2013-11-21
期刊:
Gan To Kagaku Ryoho
摘要:
The prognosis of pancreatic cancer is extremely poor in digestive cancers even with systemic therapy including surgery. Thus development of a new therapeutic approach is awaited. Recently, new trials of cancer treatments using monoclonal antibodies conjugated with anti-cancer drugs or labeled with isotopes have been reported. Here, we discuss the possible therapeutic application for pancreatic cancer of adriamycin-conjugated and 131I-labeled Nd2, which is produced against pancreatic cancer mucin.